SlideShare ist ein Scribd-Unternehmen logo
1 von 16
Copyrighted 2013, Compliance
Insight, Inc.
Top 22 Tips:
Writing for FDA Compliance
Troy Fugate
Compliance Insight, Inc.
Investigator, Auditor
Copyrighted 2013, Compliance
Insight, Inc.
This presentation will cover…
• Why we document?
• If we don’t document or document poorly,
what are the consequences.
• Good writing overview
• Report writing tips
Copyrighted 2013, Compliance
Insight, Inc.
Why document?
• It is the law!
– Thou shall document
• 211.192
– “A written record of the investigation
shall be made and shall include the
conclusions and follow-up”
• Guidance “Investigating OOS Test
Results for Pharmaceutical
Production”
Copyrighted 2013, Compliance
Insight, Inc.
Formal Documentation
• The goal is to clearly describe:
– The issue or problem
– The paths taken during the
investigation
– CAPA
– Conclusion
• Prevents errors due to oral
communication
• Prevents errors due to informal
documentation
Copyrighted 2013, Compliance
Insight, Inc.
Poor Documentation
• Examples
– None
– Confusing, unclear, vague
• Consequences
– Release bad product
– Reject good product
– Legal issues
– Reputation
• FDA
• Public
Copyrighted 2013, Compliance
Insight, Inc.
What are you going to document?
• All GMP related operations
– Manufacturing
– Packaging
– Testing
– Etc.
• Investigations
• Complaints
You are going to document
just about everything in
pharmaceutical operations
– especially dealing with
quality!!!!!
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
1. Be clear, concise and timely
2. Clearly summarize the issue
3. Include all pertinent items found during
the investigation
4. Have a conclusion
5. Indicate CAPA
6. Be approved – QA ++++
7. Be communicated to the appropriate
people
If you don’t have a
conclusion, the FDA
will make one for you!
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
8. Not assume anything
– The reader may not know
• The process (or know if very well)
• The product
• The history
8. Use charts, tables, graphs
9. Do Not use slang, jargon
10.Backup findings with evidence, data
11.Do Not exaggerate
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
13.State the scope of the problem or issue
14.Outline the root cause
15.Indicate CAPA
– Systemic approach
13.Flows well
– Paragraphs connected via some form of
thought process
13.Use bullet points as necessary
Copyrighted 2013, Compliance
Insight, Inc.
The Top 22 Tips…
18.List key dates and times
19.Timeline of the investigation
20.Contain copies of reference data
21.Contain copies of CAPA items
– Training
– Purchases
– Employee issues – NO (this is personal)
18.Be all inclusive to the incident
– Don’t stop just because you “think” you found the
problem
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Place yourself in the background
• Use nouns and verbs
– Minimal use of adjectives and adverbs
• Revise, revise, revise
– Let others not involved with the issue read the
report
– Remember, the next person to read this
report may be the FDA
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Avoid “local” or technologically advanced
wording
• Do not inject opinion
• Spell out abbreviations
• Be specific
– The product didn’t meet specifications.
– Better: Product Fugatium Bromide, Tablets,
10 mg, did not meet potency specifications of
92 – 102% as dictated in the USP. The
results were as follows:
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Select a format and stick with it
• Select a report format
– Introduction
– Outline of investigation
– Summary of investigation
– Conclusion
– CAPA
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• Put statements in a positive form
• Use definite, specific language
• Don’t include needless wording or
statements
• Check your data (calculation errors have
resulted in further problems)
Copyrighted 2013, Compliance
Insight, Inc.
How to write
• The next reader will probably be an
auditor
• Begin with the end in mind
– (i.e. What is your goal?)
• Include all areas of the investigation
– Even those that resulted in “no issues noted”
• Indicate results, expected ranges and
specifications (internal, NDA, ANDA, USP)
For More Information or Help…
• Give us a call at:
– 513-860-3512
– www.Compliance-Insight.com
– FDATrainingTeam@compliance-insight.com
– Free consultation by phone
Copyrighted 2013, Compliance
Insight, Inc.

Weitere ähnliche Inhalte

Was ist angesagt?

Data Integrity AbbVie Presentation
Data Integrity AbbVie PresentationData Integrity AbbVie Presentation
Data Integrity AbbVie Presentation
Brian Sheerin
 
FDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixesFDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixes
Vidyasagar P
 
FDA audit readiness
FDA audit readinessFDA audit readiness
FDA audit readiness
Palash Das
 
FDA Inspection Readiness.pptx
FDA Inspection Readiness.pptxFDA Inspection Readiness.pptx
FDA Inspection Readiness.pptx
GeorgeVardas2
 

Was ist angesagt? (20)

Data Integrity AbbVie Presentation
Data Integrity AbbVie PresentationData Integrity AbbVie Presentation
Data Integrity AbbVie Presentation
 
Preparing for an FDA Inspection
Preparing for an FDA InspectionPreparing for an FDA Inspection
Preparing for an FDA Inspection
 
FDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixesFDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixes
 
Fda Inspection
Fda InspectionFda Inspection
Fda Inspection
 
FDA audit readiness
FDA audit readinessFDA audit readiness
FDA audit readiness
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
 
CAPA: A Risk Mitigating Quality System
CAPA: A Risk Mitigating Quality SystemCAPA: A Risk Mitigating Quality System
CAPA: A Risk Mitigating Quality System
 
Preparing For An FDA Inspection - Employee Review
Preparing For An FDA Inspection - Employee ReviewPreparing For An FDA Inspection - Employee Review
Preparing For An FDA Inspection - Employee Review
 
FDA Inspection Readiness.pptx
FDA Inspection Readiness.pptxFDA Inspection Readiness.pptx
FDA Inspection Readiness.pptx
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).ppt
 
FDA Audit - The Do and Don't List
FDA Audit - The Do and Don't ListFDA Audit - The Do and Don't List
FDA Audit - The Do and Don't List
 
Gdp alcoa
Gdp  alcoaGdp  alcoa
Gdp alcoa
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry
 
Qualification of a Central Lab for a Clinical Trial
Qualification of a Central Lab for a Clinical TrialQualification of a Central Lab for a Clinical Trial
Qualification of a Central Lab for a Clinical Trial
 
A Risk-Based Approach for Investigating Environmental Monitoring Excursions
A Risk-Based Approach for Investigating Environmental Monitoring ExcursionsA Risk-Based Approach for Investigating Environmental Monitoring Excursions
A Risk-Based Approach for Investigating Environmental Monitoring Excursions
 
Corrective Action & Preventive Action
Corrective Action & Preventive ActionCorrective Action & Preventive Action
Corrective Action & Preventive Action
 
Gdp alcoa-160229041605-converted
Gdp alcoa-160229041605-convertedGdp alcoa-160229041605-converted
Gdp alcoa-160229041605-converted
 
Capa, root cause analysis, and risk management
Capa, root cause analysis, and risk managementCapa, root cause analysis, and risk management
Capa, root cause analysis, and risk management
 
GMP Inspection Process: Types of GMP inspection
GMP Inspection Process: Types of GMP inspectionGMP Inspection Process: Types of GMP inspection
GMP Inspection Process: Types of GMP inspection
 
Data integrity - Regulatory Perspective and Challenges:
Data integrity - Regulatory Perspective and Challenges: Data integrity - Regulatory Perspective and Challenges:
Data integrity - Regulatory Perspective and Challenges:
 

Ähnlich wie Top 22 Tips: Writing For FDA Compliance

Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docx
felicidaddinwoodie
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docx
humphrieskalyn
 
Testing & Optimization - A Deeper Look
Testing & Optimization - A Deeper LookTesting & Optimization - A Deeper Look
Testing & Optimization - A Deeper Look
Caleb Whitmore
 
, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx
madlynplamondon
 

Ähnlich wie Top 22 Tips: Writing For FDA Compliance (20)

REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
 
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
 
Drug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentDrug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory Environment
 
Best Audit Practices: The Top 10 Auditing Mistakes Companies Make
Best Audit Practices: The Top 10 Auditing Mistakes Companies MakeBest Audit Practices: The Top 10 Auditing Mistakes Companies Make
Best Audit Practices: The Top 10 Auditing Mistakes Companies Make
 
ch01.ppt
ch01.pptch01.ppt
ch01.ppt
 
Pai
PaiPai
Pai
 
Quality audit plan
Quality audit planQuality audit plan
Quality audit plan
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docx
 
Business Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docxBusiness Communication TodayFourteenth EditionChapter 13Fi.docx
Business Communication TodayFourteenth EditionChapter 13Fi.docx
 
Mike Roe Creating Client Value
Mike Roe Creating Client ValueMike Roe Creating Client Value
Mike Roe Creating Client Value
 
Ensuring FDA Regulatory Success for Biomedical Companies
Ensuring FDA Regulatory Success for Biomedical CompaniesEnsuring FDA Regulatory Success for Biomedical Companies
Ensuring FDA Regulatory Success for Biomedical Companies
 
Lecture 8 Resources and Costs.pptx
Lecture 8 Resources and Costs.pptxLecture 8 Resources and Costs.pptx
Lecture 8 Resources and Costs.pptx
 
Documentation: First & Last Exit in GMP
Documentation: First & Last Exit in GMP Documentation: First & Last Exit in GMP
Documentation: First & Last Exit in GMP
 
Testing & Optimization - A Deeper Look
Testing & Optimization - A Deeper LookTesting & Optimization - A Deeper Look
Testing & Optimization - A Deeper Look
 
5 Proven Strategies For a Successful Analytics Product Launch
5 Proven Strategies For a Successful Analytics Product Launch5 Proven Strategies For a Successful Analytics Product Launch
5 Proven Strategies For a Successful Analytics Product Launch
 
Testing the unknown: the art and science of working with hypothesis
Testing the unknown: the art and science of working with hypothesisTesting the unknown: the art and science of working with hypothesis
Testing the unknown: the art and science of working with hypothesis
 
Regulatory Considerations in Product Development
Regulatory Considerations in Product DevelopmentRegulatory Considerations in Product Development
Regulatory Considerations in Product Development
 
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
 
, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx, please see the feedback within your paper and in the scoring rub.docx
, please see the feedback within your paper and in the scoring rub.docx
 
Exaudio, llc Background + MR capabilities
Exaudio, llc Background + MR capabilitiesExaudio, llc Background + MR capabilities
Exaudio, llc Background + MR capabilities
 

Mehr von Compliance Insight, Inc.

Mehr von Compliance Insight, Inc. (14)

July 2015
July 2015July 2015
July 2015
 
GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.
 
FDA audit series part 5, dealing with the 483 or Warning Letter
FDA audit series   part 5, dealing with the 483 or Warning LetterFDA audit series   part 5, dealing with the 483 or Warning Letter
FDA audit series part 5, dealing with the 483 or Warning Letter
 
FDA audit series part 4, the closeout
FDA audit series   part 4, the closeoutFDA audit series   part 4, the closeout
FDA audit series part 4, the closeout
 
Fda audit series part 3, while the fda is there
Fda audit series   part 3, while the fda is  thereFda audit series   part 3, while the fda is  there
Fda audit series part 3, while the fda is there
 
FDA audit series part 2, what to do when the FDA arrives
FDA audit series   part 2, what to do when the FDA arrivesFDA audit series   part 2, what to do when the FDA arrives
FDA audit series part 2, what to do when the FDA arrives
 
FDA audit series part 1, Preparing for the Audit
FDA audit series   part 1, Preparing for the AuditFDA audit series   part 1, Preparing for the Audit
FDA audit series part 1, Preparing for the Audit
 
About Compliance Insight Inc.
About Compliance Insight Inc.About Compliance Insight Inc.
About Compliance Insight Inc.
 
FDA 483 observations in the lab
FDA 483 observations in the labFDA 483 observations in the lab
FDA 483 observations in the lab
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
 
FDA GMP Training - The Quality Audit
FDA GMP Training - The Quality AuditFDA GMP Training - The Quality Audit
FDA GMP Training - The Quality Audit
 
21 cfr, parts 210 211
21 cfr, parts 210 21121 cfr, parts 210 211
21 cfr, parts 210 211
 
FDA Warning Letter
FDA Warning LetterFDA Warning Letter
FDA Warning Letter
 
FDA 483
FDA 483FDA 483
FDA 483
 

Kürzlich hochgeladen

Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pillsMifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Abortion pills in Kuwait Cytotec pills in Kuwait
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
daisycvs
 
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan CytotecJual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
ZurliaSoop
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for Viewing
Nauman Safdar
 
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in OmanMifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
instagramfab782445
 
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabiunwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
Abortion pills in Kuwait Cytotec pills in Kuwait
 

Kürzlich hochgeladen (20)

Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pillsMifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
Mifty kit IN Salmiya (+918133066128) Abortion pills IN Salmiyah Cytotec pills
 
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60%  in 6 MonthsSEO Case Study: How I Increased SEO Traffic & Ranking by 50-60%  in 6 Months
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
 
Power point presentation on enterprise performance management
Power point presentation on enterprise performance managementPower point presentation on enterprise performance management
Power point presentation on enterprise performance management
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
 
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan CytotecJual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan Cytotec
 
Uneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration PresentationUneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration Presentation
 
BeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfBeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdf
 
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1
 
New 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck TemplateNew 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck Template
 
Organizational Transformation Lead with Culture
Organizational Transformation Lead with CultureOrganizational Transformation Lead with Culture
Organizational Transformation Lead with Culture
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for Viewing
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation Final
 
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in OmanMifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
 
Rice Manufacturers in India | Shree Krishna Exports
Rice Manufacturers in India | Shree Krishna ExportsRice Manufacturers in India | Shree Krishna Exports
Rice Manufacturers in India | Shree Krishna Exports
 
Phases of Negotiation .pptx
 Phases of Negotiation .pptx Phases of Negotiation .pptx
Phases of Negotiation .pptx
 
Buy Verified TransferWise Accounts From Seosmmearth
Buy Verified TransferWise Accounts From SeosmmearthBuy Verified TransferWise Accounts From Seosmmearth
Buy Verified TransferWise Accounts From Seosmmearth
 
Falcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business Growth
 
Pre Engineered Building Manufacturers Hyderabad.pptx
Pre Engineered  Building Manufacturers Hyderabad.pptxPre Engineered  Building Manufacturers Hyderabad.pptx
Pre Engineered Building Manufacturers Hyderabad.pptx
 
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabiunwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
 

Top 22 Tips: Writing For FDA Compliance

  • 1. Copyrighted 2013, Compliance Insight, Inc. Top 22 Tips: Writing for FDA Compliance Troy Fugate Compliance Insight, Inc. Investigator, Auditor
  • 2. Copyrighted 2013, Compliance Insight, Inc. This presentation will cover… • Why we document? • If we don’t document or document poorly, what are the consequences. • Good writing overview • Report writing tips
  • 3. Copyrighted 2013, Compliance Insight, Inc. Why document? • It is the law! – Thou shall document • 211.192 – “A written record of the investigation shall be made and shall include the conclusions and follow-up” • Guidance “Investigating OOS Test Results for Pharmaceutical Production”
  • 4. Copyrighted 2013, Compliance Insight, Inc. Formal Documentation • The goal is to clearly describe: – The issue or problem – The paths taken during the investigation – CAPA – Conclusion • Prevents errors due to oral communication • Prevents errors due to informal documentation
  • 5. Copyrighted 2013, Compliance Insight, Inc. Poor Documentation • Examples – None – Confusing, unclear, vague • Consequences – Release bad product – Reject good product – Legal issues – Reputation • FDA • Public
  • 6. Copyrighted 2013, Compliance Insight, Inc. What are you going to document? • All GMP related operations – Manufacturing – Packaging – Testing – Etc. • Investigations • Complaints You are going to document just about everything in pharmaceutical operations – especially dealing with quality!!!!!
  • 7. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 1. Be clear, concise and timely 2. Clearly summarize the issue 3. Include all pertinent items found during the investigation 4. Have a conclusion 5. Indicate CAPA 6. Be approved – QA ++++ 7. Be communicated to the appropriate people If you don’t have a conclusion, the FDA will make one for you!
  • 8. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 8. Not assume anything – The reader may not know • The process (or know if very well) • The product • The history 8. Use charts, tables, graphs 9. Do Not use slang, jargon 10.Backup findings with evidence, data 11.Do Not exaggerate
  • 9. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 13.State the scope of the problem or issue 14.Outline the root cause 15.Indicate CAPA – Systemic approach 13.Flows well – Paragraphs connected via some form of thought process 13.Use bullet points as necessary
  • 10. Copyrighted 2013, Compliance Insight, Inc. The Top 22 Tips… 18.List key dates and times 19.Timeline of the investigation 20.Contain copies of reference data 21.Contain copies of CAPA items – Training – Purchases – Employee issues – NO (this is personal) 18.Be all inclusive to the incident – Don’t stop just because you “think” you found the problem
  • 11. Copyrighted 2013, Compliance Insight, Inc. How to write • Place yourself in the background • Use nouns and verbs – Minimal use of adjectives and adverbs • Revise, revise, revise – Let others not involved with the issue read the report – Remember, the next person to read this report may be the FDA
  • 12. Copyrighted 2013, Compliance Insight, Inc. How to write • Avoid “local” or technologically advanced wording • Do not inject opinion • Spell out abbreviations • Be specific – The product didn’t meet specifications. – Better: Product Fugatium Bromide, Tablets, 10 mg, did not meet potency specifications of 92 – 102% as dictated in the USP. The results were as follows:
  • 13. Copyrighted 2013, Compliance Insight, Inc. How to write • Select a format and stick with it • Select a report format – Introduction – Outline of investigation – Summary of investigation – Conclusion – CAPA
  • 14. Copyrighted 2013, Compliance Insight, Inc. How to write • Put statements in a positive form • Use definite, specific language • Don’t include needless wording or statements • Check your data (calculation errors have resulted in further problems)
  • 15. Copyrighted 2013, Compliance Insight, Inc. How to write • The next reader will probably be an auditor • Begin with the end in mind – (i.e. What is your goal?) • Include all areas of the investigation – Even those that resulted in “no issues noted” • Indicate results, expected ranges and specifications (internal, NDA, ANDA, USP)
  • 16. For More Information or Help… • Give us a call at: – 513-860-3512 – www.Compliance-Insight.com – FDATrainingTeam@compliance-insight.com – Free consultation by phone Copyrighted 2013, Compliance Insight, Inc.